Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
142 studies found for:    "AL amyloidosis"
Show Display Options
RSS Create an RSS feed from your search for:
"AL amyloidosis"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Radioimmunoimaging of AL Amyloidosis
Condition: AL Amyloidosis
Intervention: Biological: 124I-labeled monoclonal antibody Mu 11-1F4
2 Suspended Trial of HDM/SCT Versus HDM + Bortezomib/SCT in AL Amyloidosis
Condition: AL Amyloidosis
Interventions: Drug: Bortezomib;   Drug: Melphalan;   Drug: Neupogen;   Procedure: Stem Cell Collection;   Procedure: Stem cell infusion
3 Active, not recruiting Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis
Condition: AL Amyloidosis
Interventions: Drug: Bendamustine;   Drug: Dexamethasone
4 Not yet recruiting Daratumumab for the Treatment of Patients With AL Amyloidosis
Condition: AL Amyloidosis
Intervention: Drug: daratumumab
5 Active, not recruiting A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis
Condition: AL Amyloidosis
Interventions: Drug: Pomalidomide;   Drug: Dexamethasone
6 Completed Radioimmunoimaging of Light Chain (AL) Amyloidosis
Condition: AL Amyloidosis
Intervention: Biological: Single infusion of 124I-labeled anti-amyloid mAb 11-1F4: 2 mCi (1 mg)
7 Completed Allo SCT in Amyloidosis Non-interventional Study
Condition: AL Amyloidosis
Intervention:
8 Active, not recruiting Quality of Life (QOL) Registry for Patients With AL Amyloidosis
Conditions: AL Amyloidosis;   Amyloidosis
Intervention: Other: non-interventional
9 Completed Radioimmunoimaging of AL Amyloidosis
Condition: Primary Amyloidosis
Intervention: Biological: 124I-labeled monoclonal antibody Mu 11-1F4
10 Recruiting Epigallocatechingallate (EGCG) in Cardiac AL Amyloidosis
Condition: Primary Amyloidosis of Light Chain Type
Interventions: Drug: Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhithmias);   Drug: Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhythmias) plus EGCG
11 Active, not recruiting Pomalidomide and Dexamethasone (PDex) in AL Amyloidosis
Condition: Primary Amyloidosis of Light Chain Type
Intervention: Drug: Pomalidomide and Dexamethasone
12 Suspended High Cut-off Hemodialysis in Patients With Advanced Cardiac AL Amyloidosis and End Stage Renal Disease
Condition: Primary Amyloidosis of Light Chain Type
Interventions: Device: High Cut-off Hemodialysis;   Drug: Chemotherapy
13 Recruiting The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis
Condition: AL Amyloidosis
Interventions: Drug: NEOD001;   Drug: Placebo
14 Active, not recruiting Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis
Condition: AL Amyloidosis
Intervention: Drug: NEOD001
15 Completed A Trial for Systemic Light-chain (AL) Amyloidosis
Condition: AL Amyloidosis
Intervention: Drug: BMDex
16 Recruiting Minimal Residual Disease as a Possible Predictive Factor for Relapse in Patients With AL Amyloidosis
Conditions: Amyloidosis;   Primary Amyloidosis
Intervention:
17 Recruiting First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD
Conditions: Light Chain Deposition Disease;   Primary Systemic Amyloidosis
Interventions: Drug: pomalidomide;   Drug: bortezomib;   Drug: dexamethasone;   Other: Laboratory Biomarker Analysis
18 Completed A Trial of Treatment With Lenalidomide-Melphalan-Dexamethasone in Patients With Primary (AL) Amyloidosis
Condition: Primary Amyloidosis
Intervention: Drug: Lenalidomide
19 Recruiting Assessment of Minimal Residual Disease (MRD) After Antineoplastic Treatment in Patients With AL Amyloidosis
Condition: Amyloidosis
Interventions: Other: blood collection;   Other: bone marrow collection
20 Active, not recruiting
Has Results
Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease
Conditions: Primary Systemic Amyloidosis;   Light Chain Deposition Disease
Interventions: Drug: bortezomib;   Drug: dexamethasone;   Drug: melphalan;   Genetic: microarray analysis;   Other: flow cytometry;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.